DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.

DNA methylation biomarkers predict progression-free and overall survival of metastatic renal cell cancer (mRCC) treated with antiangiogenic therapies.

VEGF-targeted therapy increases both the progression-free (PFS) and overall survival (OS) of patients with metastasized renal cell cancer (mRCC). Identification of molecular phenotypes of RCC could improve risk-stratification and the prediction of the clinical disease course. We investigated whether...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Inga Peters, Natalia Dubrowinskaja, Mahmoud Abbas, Christoph Seidel, Michael Kogosov, Ralph Scherer, Kai Gebauer, Axel S Merseburger, Markus A Kuczyk, Viktor Grünwald, Jürgen Serth
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Public Library of Science (PLoS) 2014-01-01
Sarja:PLoS ONE
Linkit:http://europepmc.org/articles/PMC3954691?pdf=render

Internet

http://europepmc.org/articles/PMC3954691?pdf=render

Samankaltaisia teoksia